-
Manufacturing & Capacity Response
Production Lines and Installed Capacity
Carlos Pharmaceuticals operates a fully integrated pharmaceutical manufacturing facility with multiple dosage‑form production lines supported by centralized utilities (WFI, PW, pure steam, HVAC, compressed air, boiler systems, and standby power generation). The facility is designed to support large‑scale commercial manufacturing as well as third‑party production.
The installed production capacity across key dosage forms includes:
This multi‑dosage capability enables the facility to support a wide pharmaceutical and healthcare product portfolio, including OTC medicines, prescription products, topical formulations, sterile preparations, and powder‑based sachets.
-
Tablets:
480 million tablets per year (effective capacity of approximately 400–450 million tablets annually).
-
Capsules
118.8 million capsules per year (effective capacity of approximately 100–110 million capsules annually).
-
Liquid Syrups & Suspensions
12 million bottles per year (effective capacity of approximately 9.6 million bottles annually).
-
Creams, Ointments & Lotions:
330,000 kg per year.
-
Sterile Eye and Ear Drops
9 million bottles per year (effective capacity of approximately 7.2 million bottles annually).
-
Sachet and Dry Powder Products
14.4 million sachets per year.
Contract Manufacturing Services
Carlos Pharma is structured to support contract manufacturing as part of its market expansion strategy, leveraging its diversified production lines and substantial installed capacity. The facility is suitable for third‑party manufacturing of:
Solid dosage forms:
Tablets and capsules
Liquid dosage forms:
Syrups and suspensions
Semi‑solid products:
Creams, ointments, and lotions
Sterile products:
Eye and ear drops
Powdered products:
Sachet‑filled dry powders
Contract manufacturing volumes can be accommodated within the listed installed and effective capacities of each production line, subject to product type, batch size, and regulatory requirements. The operation is supported by in‑house quality assurance, quality control, microbiology, and regulatory documentation systems, aligning with NAFDAC registration and compliance planning outlined in the master document.
Enquiries for contract manufacturing are expected to be initiated through formal engagement with Carlos Pharma’s management or business development team, where product specifications, target volumes, regulatory status, and production timelines can be reviewed and aligned with available capacity.